Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

Cancer

Volumn 115, Issue 2, 2009, Pages 373-380

  Tsimberidou, Apostolia Maria ^a   Tam, Constantine ^a   Abruzzo, Lynne V ^a   O'Brien, Susan ^a   Wierda, William G ^a   Lerner, Susan ^a   Kantarjian, Hagop M ^a   Keating, Michael J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

11q deletion; ATM; CLL; FCR; FISH

Indexed keywords

ALEMTUZUMAB; ATM PROTEIN; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MITOXANTRONE; PREDNISONE; PROTEIN P53; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DATA BASE; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE LOCUS; HUMAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; SPLENOMEGALY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRISOMY 12;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 59449110380     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23993     Document Type: Article

References (33)

1. Gatti RA, Berkel I, Boder E, et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature. 1988;336:577-580.
2. Taylor AM, Harnden DG, Arlett CF, et al. Ataxia telan- giectasia: a human mutation with abnormal radiation sensitivity. Nature. 1975;258:427-429.
3. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268:1749-1753.
4. Bullrich F, Rasio D, Kitada S, et al. ATM mutations in B- cell chronic lymphocytic leukemia. Cancer Res. 1999;59:24-27.
5. Schaffner C, Stilgenbauer S, Rappold GA, Dohner H, Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood. 1999;94:748-753.
6. Stankovic T, Weber P, Stewart G, et al. Inactivation of ataxia telangiectasia mutated gene in B- cell chronic lympho- cytic leukaemia. Lancet. 1999;353:26-29.
7. Stankovic T, Stewart GS, Fegan C, et al. Ataxia telangiecta- sia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood. 2002;99:300-309.
8. Parikh RA, White JS, Huang X, et al. Loss of distal 11q is associated with DNA repair deficiency and reduced sensitivity to ionizing radiation in head and neck squamous cell carcinoma. Genes Chromosomes Cancer. 2007;46:761-775.
9. Barlow C, Hirotsune S, Paylor R, et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell. 1996;86:159-171.
10. Xu Y, Ashley T, Brainerd EE, Bronson RT, Meyn MS, Baltimore D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 1996;10: 2411-2422.
11. Dohner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B- cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood. 1997;89:2516-2522.
12. Fegan C, Robinson H, Thompson P, Whittaker JA, White D. Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia. 1995;9:2003-2008.
13. Neilson JR, Auer R, White D, et al. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia. 1997;11:1929-1932.
14. Ross FM, Stockdill G. Clonal chromosome abnormalities in chronic lymphocytic leukemia patients revealed by TPA stimulation of whole blood cultures. Cancer Genet Cytogenet. 1987;25:109-121.
15. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. NEngl J Med. 2000;343:1910-1916.
16. Rai K, Patel DV. Chronic lymphocytic leukemia. In: He- matology. Basic Principles and Practice. 3rd ed. Philadelphia, PA: Churchill Livingstone; 2000:1350-1363.
17. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
18. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:1414- 1420.
19. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophos- phamide, and rituximab as initial therapy for chronic lym- phocytic leukemia. J Clin Oncol. 2005;23:4079-4088.
20. McLaughlin P, Liu N, Poindexter N, et al. Rituximab plus GM- CSF for indolent lymphoma [abstract]. Proceedings of the 9th International Conference on Malignant Lympho- mas, Lugano, Switzerland. Ann Oncol. 2005;16(suppl 5):104. Abstract 68.
21. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370:230-239.
22. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B- cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1990; 323:720-724.
23. Hernandez J M, Mecucci C, Criel A, et al. Cytogenetic analysis of B cell chronic lymphoid leukemias classified according to morphologic and immunophenotypic (FAB) criteria. Leukemia. 1995;9:2140-2146.
24. Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia. 2007;21:2442-2451.
25. Starostik P, Manshouri T, O'Brien S, et al. Deficiency of the ATM protein expression defines an aggressive subgroup of B- cell chronic lymphocytic leukemia. Cancer Res. 1998; 58:4552-4557.
26. Faderl S, Keating M J, Do KA, et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2002; 16:1045-1052.
27. Tsimberidou AM, Wen S, O'Brien S, et al. Assessment of chronic lymphocytic leukemia and small lymphocytic lym- phoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2007;25:4648-4656.
28. Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemo- immunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006;24:437-443.
29. Caballero D, Garcia-Marco JA, Martino R, et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B- cell chronic lym- phocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res. 2005;11:7757-7763.
30. Austen B, Powell JE, Alvi A, et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B- CLL. Blood. 2005;106:3175-3182.
31. Haslinger C, Schweifer N, Stilgenbauer S, et al. Microarray gene expression profiling of B- cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol. 2004;22:3937-3949.
32. Joshi AD, Hegde GV, Dickinson JD, et al. ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B- cell chronic lymphocytic leukemia. Clin Cancer Res. 2007;13:5295-5304.
33. Austen B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol. 2007;25:5448-5457